LY2109761,
LY2109761,
700874-71-1,
LY 2109761,
LY-2109761,
4-(2-((4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yl)oxy)ethyl)morpholine,
4-(2-(4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yloxy)ethyl)morpholine,
C26H27N5O2,
4-[5,6-Dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[2-(4-morpholinyl)ethoxy]quinoline,
IHLVSLOZUHKNMQ-UHFFFAOYSA-N,
Dihydropyrrolopyrazole, 15d,
MLS006010968,
CHEMBL260015,
GTPL8075,
SCHEMBL3737735,
BDBM21509,
KS-00000XPQ,
DTXSID30470111,
EX-A071,
BCP02824,
ABP001002,
MFCD12923354,
s2704,
ZINC14976393,
AKOS022183732,
BCP9000868,
CS-0571,
QC-7261,
RL04685,
SB19481,
NCGC00242598-01,
NCGC00242598-03,
4CA-0771,
AC-30289,
AJ-65535,
AK-83152,
BC635842,
HY-12075,
SC-86319,
SMR004702772,
AB0008023,
FT-0698866,
ST24042818,
Y0460,
A11133,
W-5549,
J-514249,
LY2109761,CAS:700874-71-1,
700874-71-1 pound not LY-2109761 pound not LY 2109761,
4-[2-({4-[2-(pyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-a]pyrazol-3-yl]quinolin-7-yl}oxy)ethyl]morpholine,
4-[2-[4-(2-Pyridin-2-yl-5,6-dihydro-4H-pyrrolo[2,1-e]pyrazol-3-yl)quinolin-7-yl]oxyethyl]morpholine,
7-(2-morpholin-4-yl-ethoxy)-4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-quinoline,
7-(2-morpholin-4-ylethoxy)-4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[2,1-e]pyrazol-3-yl)quinoline,
STREPTOZOTOCIN,
D06KKN,
cc-120,
CID11655119,
A8464,
C530108,
18883-66-4,
4-(2-(4-(2-(pyridin-2-yl)-3a,4,5,6-tetrahydro-3H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yloxy)ethyl)morpholine,
7-(2-morpholin-4-ylethoxy)-4-(7-pyridin-2-yl-1,8-diazabicyclo[3.3.0]octa-5,7-dien-6-yl)quinoline,
LY2109761, 98%, a novel selective TGF-beta receptor type I/II (TbetaRI/II) dual inhibitor - 25MG 25mg,